Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.242529
Abstract: Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, there is limited data about the optimal duration of treatment and the risk of relapse after anti-PD1 discontinuation.… read more here.
Keywords: pd1; anti pd1; pd1 treatment; pd1 discontinuation ... See more keywords